OBJECTIVES HIV is a life-threatening disease in terms of a major global public health problem. This analysis evaluates the cost-effectiveness comparison of HIV-1 treatment alternatives including lamivudine+zidovudine+efavirenz (3TC/AZT+EFV), tenofovir DF+emtricitabine+efavirenz (FTC/TDF+EFV), tenofovir DF+emtricitabine+ritonavir+ lopinavir (FTC/TDF+LPV/r), tenofovir DF+emtricitabine+ darunavir (FTC/TDF+ DRV+ r), and elvitegravir+cobicistat+emtricitabine+tenofovir DF (STRIBILD). METHODS This analysis compares the HIV treatment alternatives of 3TC/AZT+ EFV, FTC/TDF+EFV, FTC/TDF+LPV/r, FTC/TDF+DRV+ r and STRIBILD. The adherence rates were calculated from the increase rate in CD4 cell count and the risk of hospitalization as the effectiveness values. The data were taken from patient files from Hacettepe University that consists of 252 patients and 12 year follow-ups with an outpatient clinic, interventions,  laboratory and imaging tests, medication usage, side effects, comorbidity's diseases and their treatments and complications. The costs of treatment of diseases were calculated by cost of disease methodology. Average annual cost per patient is calculated for healthcare technologies. Health technology effectiveness values are found from the literature review. Virological response success is used from clinical studies as an end-point for this analysis. The treatment cost comparison is calculated with the incremental cost effectiveness-ratio (ICER). RESULTS Results of the clinical effectiveness of the treatment alternatives of 3TC/AZT+ EFV, FTC/TDF + EFV, FTC/TDF +LPV/r, FTC/TDF+ DRV+ r and STRIBILD were  58%,  75%,  78%, 84%,  and  88%, respectively. In the cost -effectiveness comparison analysis, the annual total treatment costs are calculated as 12531 TL, 17524 TL, 24284 TL, 22987 TL, and 20868 TL, respectively. The total ICER analysis shows only STRIBILD, FTC/TDF+EFV and 3TC/AZT+EFV treatments are cost-effective, while the other treatment alternatives are not cost-effective. CONCLUSIONS The HIV-1 treatment study was conducted in Turkey on the cost-effectiveness of this treatment strategy.  The clinical efficacy and the cost-effectiveness of STRIBILD shows that it is an effective treatment strategy for HIV patients.